Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. (Q64948328)

1 July 2019

title

Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. (English)

1 reference

1 July 2019

1 reference

12

Rachel Schneerson

1 reference

1 July 2019

Joseph Shiloach

10

object named as

Joseph Shiloach

1 reference

1 July 2019

author name string

Justen H Passwell

1

1 reference

1 July 2019

Shai Ashkenzi

2

1 reference

1 July 2019

Yonit Banet-Levi

3

1 reference

1 July 2019

Reut Ramon-Saraf

4

1 reference

1 July 2019

Nahid Farzam

5

1 reference

1 July 2019

Liat Lerner-Geva

6

1 reference

1 July 2019

Hadas Even-Nir

7

1 reference

1 July 2019

Baruch Yerushalmi

8

1 reference

1 July 2019

Chiayung Chu

9

1 reference

1 July 2019

John B Robbins

11

1 reference

1 July 2019

Israeli Shigella Study Group

13

1 reference

1 July 2019

language of work or name

English

0 references

publication date

5 January 2010

1 reference

1 July 2019

published in

Vaccine

1 reference

1 July 2019

volume

28

1 reference

1 July 2019

issue

10

1 reference

1 July 2019

page(s)

2231-2235

1 reference

1 July 2019

Laboratory-confirmed shigellosis in the United States, 1989-2002: epidemiologic trends and patterns

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

The Shigella flexneri O-antigenic polysaccharide chain Nature of the biological repeating unit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Structural Studies of Shigella flexneri O-Antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnei

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Shigella lipopolysaccharide antibodies in pediatric populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Somatic Antigens of Shigella. The Structure of the Specific Polysaccharide of Shigella newcastle (Sh. flexneri type 6) Lipopolysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Molecular characterization of the genes involved in O-antigen modification, attachment, integration and excision in Shigella flexneri bacteriophage SfV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Structure and genetics of Shigella O antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

7 January 2021

Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

7 January 2021

Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

7 January 2021

Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.12.050

7 January 2021

Global burden of Shigella infections: implications for vaccine development and implementation of control strategies

1 reference

12 December 2020

Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid.

1 reference

12 December 2020

Serology, chemistry, and genetics of O and K antigens of Escherichia coli

1 reference

12 December 2020

Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains

1 reference

12 December 2020

Strategy for cross-protection among Shigella flexneri serotypes

1 reference

12 December 2020

10.1016/J.VACCINE.2009.12.050

Identifiers

DOI

1 reference

1 July 2019

PMC publication ID

6503522

1 reference

1 July 2019

PubMed publication ID

20056180

1 reference

1 July 2019